Literature DB >> 16542834

Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer.

Alexandra M Santos1, Hugo Sousa, Daniela Pinto, Catarina Portela, Deolinda Pereira, Raquel Catarino, Isabel Duarte, Carlos Lopes, Rui Medeiros.   

Abstract

TP53 and its downstream effector gene P21 are two important genes in cell cycle regulation. Genetic alterations on p53 and attenuation of p21 expression result in progression through cell cycle G1 checkpoint, which can lead to cancer development. We analysed the frequency of TP53 codon 72 and 3'UTR P21 polymorphisms in 681 blood samples from 371 cervical cancer patients, 122 ovarian cancer patients and 188 healthy controls using AS-PCR and PCR-RFLP. Approximately twofold increased risk of ovarian cancer (OC) was observed for TP53 Pro carriers (P = 0.038), with a significantly higher risk for advanced OC (P = 0.018). Furthermore, among the P21 CC genotypes, TP53 P allele was also associated with a twofold increased risk of OC (P = 0.014) and to a threefold increased risk for advanced OC (P = 0.003) with an attributable proportion of 44.2%. These results were confirmed in an age-adjusted logistic regression analysis. No association was found between these polymorphisms and cervical cancer. Our results suggest that the TP53 codon 72 genotypes may be considered as a molecular marker, contributing to a genetic profile for ovarian cancer in women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16542834     DOI: 10.1016/j.ejca.2006.01.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.

Authors:  Su-Qin Shen; De-Ke Jiang; Guo-Yuan Liu; Fang Chen; Long Yu
Journal:  Mol Biol Rep       Date:  2011-09-28       Impact factor: 2.316

2.  TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer.

Authors:  Ana Coelho; Augusto Nogueira; Sílvia Soares; Joana Assis; Deolinda Pereira; Isabel Bravo; Raquel Catarino; Rui Medeiros
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

3.  Association of p21 SNPs and risk of cervical cancer among Chinese women.

Authors:  Ning Wang; Shizhuo Wang; Qiao Zhang; Yanming Lu; Heng Wei; Wei Li; Shulan Zhang; Duo Yin; Yangling Ou
Journal:  BMC Cancer       Date:  2012-12-11       Impact factor: 4.430

4.  The human Tp53 Arg72Pro polymorphism explains different functional prognosis in stroke.

Authors:  Jose C Gomez-Sanchez; Maria Delgado-Esteban; Irene Rodriguez-Hernandez; Tomas Sobrino; Natalia Perez de la Ossa; Silvia Reverte; Juan P Bolaños; Rogelio Gonzalez-Sarmiento; Jose Castillo; Angeles Almeida
Journal:  J Exp Med       Date:  2011-02-28       Impact factor: 14.307

5.  A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer.

Authors:  Koushik Chattopadhyay
Journal:  Indian J Hum Genet       Date:  2011-09

6.  Expression of p53, Ki67, epidermal growth factor receptor, transforming growth-factorα, and p21 in primary and secondary hyperparathyroidism.

Authors:  Saime Paydas; Arbil Acikalim; Bulent Kaya; Bermal Hasbay Bicer; Mehmet Ulker; Orhan Demircan; Aysun Uguz; Mustafa Balal; Gurhan Sakman; Yasar Sertdemir; Refika Karaer; Eda Altun
Journal:  Indian J Endocrinol Metab       Date:  2014-11

7.  Microarray-based cancer prediction using soft computing approach.

Authors:  Xiaosheng Wang; Osamu Gotoh
Journal:  Cancer Inform       Date:  2009-05-26

8.  Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer.

Authors:  Sandra Costa; Daniela Pinto; Deolinda Pereira; Helena Rodrigues; Jorge Cameselle-Teijeiro; Rui Medeiros; Fernando Schmitt
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

9.  Evaluating the association between p53 codon 72 Arg>pro polymorphism and risk of ovary cancer: a meta-analysis.

Authors:  Mohammed A A Alqumber; Naseem Akhter; Shafiul Haque; Aditya K Panda; Raju K Mandal
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

10.  No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects.

Authors:  Anqi Zhang; Ting-Yan Shi; Yuan Zhao; Junmiao Xiang; Danyang Yu; Zongwen Liang; Chaoyi Xu; Qiong Zhang; Yue Hu; Danhan Wang; Jing He; Ping Duan
Journal:  Oncotarget       Date:  2017-11-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.